We propose that combination therapy with inhibitor targeting KDM5C enzymatic activity and KDM5C/ZMYND8 interaction or ERα antagonist would be efficacious in battling and/or provide an additional therapeutic adjunct for ER‐positive and endocrine therapy‐resistance breast cancers. Here, ZMYND8 is linked to breast carcinoma.